Galderma market expansion and SMI inclusion

Galderma is experiencing significant financial growth and market expansion. CEO Flemming Ørnskov has attributed high revenue growth to product innovation and expansion into markets such as China, India, Latin America, and the United States. Key products driving performance include the skin medication Nemluvio and the biostimulator Sculptra.

Following this growth, Galderma has officially joined the Swiss Market Index (SMI), becoming a constituent of the benchmark index comprising 20 of Switzerland’s largest and most liquid listed companies. This milestone occurs less than three years after the company’s March 2024 IPO.

Financial reports indicate net sales rose from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, with a 24.6% year-on-year increase in the first half of 2026 at constant currency. Consequently, the company raised its full-year 2026 net sales growth guidance to between 19% and 21% at constant currency. The L’Oréal Group remains a major shareholder, holding 20% of the company.